Related Experiment Video
Updated: Aug 5, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Metabolic syndrome and increased inflammatory burden in active rheumatoid arthritis: An exploratory focus on
Amina Arroul-Lammali1, Dalila Mezioug1, Rayene Mammeri2
1Laboratory of Cellular and Molecular Biology (LBCM), Cytokines and NO Synthases Team, Faculty of Biological Sciences, USTHB (University of Sciences and Technology), Algiers, Algeria.
Abstract:
Metabolic syndrome (MetS) is associated with increased inflammatory burden in rheumatoid arthritis (RA). This study compared inflammatory markers between active RA patients with and without MetS and evaluated context-specific diagnostic thresholds. We included patients with RA-MetS (n = 30), RA (n = 30), MetS (n = 30), and healthy controls (n = 25). Plasma nitric oxide (NO), interleukins (IL-6, IL-17 A, IL-10), neutrophil-to-lymphocyte (NLR) and platelet-to-lymphocyte (PLR) ratios were measured. ROC analysis defined disease activity cut-offs. The RA-MetS group exhibited higher NO, IL-6, and IL-17 A levels versus all groups (p < 0.0001). The presence of MetS was associated with altered cut-offs: NLR was higher (>2.135 vs. >1.830 in RA) and PLR lower (>97.84 vs. >118.3). NLR correlated positively with NO in the RA-MetS (r = 0.4467, p = 0.045). Thus, MetS is associated with a distinct inflammatory signature in RA. The observed shift in NLR/PLR thresholds requires validation in larger cohorts. These accessible biomarkers are promising for personalized management of RA with comorbid MetS.
Related Concept Videos
The JAK-STAT Signaling Pathway
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Rheumatic Heart Disease I: Introduction